Clinical Trials Browser

Head and Neck Neoplasms × Radiation Dose Hypofractionation × 30 days × Clear all

NCT07447570 2026-03-03

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms